Bristol-Myers Squibb has unveiled positive topline data from a late-stage trial for its chimeric antigen receptor T-cell therapy Breyanzi, or lisocabtagene maraleucel, for relapsed or refractory large B-cell lymphoma as a second-line treatment. The treatment was compared with standard regimens in adults who are stem cell transplant-eligible, whose disease is primary refractory or who relapsed less than a year after initial therapy, with Breyanzi "demonstrating a 'highly' statistically significant improvement in event-free survival compared to standard of care."